|
Market Closed -
Sao Paulo
03:50:32 2026-10-16 pm EDT
|
5-day change | 1st Jan Change | ||
| 78.56 BRL | -2.65% |
|
+5.78% | +19.10% |
| Oct. 16 | EU Medicines Agency Panel Backs CuraTeQ Biologics' Neupogen Biosimilar for Neutropenia | MT |
| Oct. 15 | Goldman Sachs Adjusts Price Target on Amgen to $481 From $475 | MT |
| Market Cap | 234B 1,185B 208B 193B 175B 331B 22,201B 337B 2,314B 908B 11,576B 877B 859B 36,940B | P/E 2026 * |
27.5x | P/E 2027 * | 24.5x |
|---|---|---|---|---|---|
| Enterprise Value | 275B 1,395B 245B 227B 206B 389B 26,128B 396B 2,723B 1,069B 13,624B 1,033B 1,011B 43,474B | EV / Sales 2026 * |
7.06x | EV / Sales 2027 * | 6.67x |
| Free-Float |
99.77% | Yield 2026 * |
2.33% | Yield 2027 * | 2.46% |
Last Transcript: Amgen Inc.
| 1 day | -2.65% | ||
| 1 week | +5.78% | ||
| Current month | +0.42% | ||
| 1 month | +13.49% | ||
| 3 months | +16.89% | ||
| 6 months | +26.24% | ||
| Current year | +19.10% |
| 1 week | 73.99 |  | 79.84 |
| 1 month | 69.26 | | 79.84 |
| Current year | 48.4 | | 83.38 |
| 1 year | 48.4 | | 83.38 |
| 3 years | 45.12 | | 83.38 |
| 5 years | 37.52 | | 83.38 |
| 10 years | 15.78 | | 83.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
| Director of Finance/CFO | 62 | 2010-05-12 | |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 57 | 2023-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.65% | +5.78% | - | - | 235B | |
| +0.43% | +7.48% | +52.08% | +106.34% | 1,116B | |
| +0.90% | -0.36% | +33.68% | +62.93% | 610B | |
| +0.71% | +4.77% | +26.17% | +92.90% | 501B | |
| +0.52% | +2.51% | +73.52% | +40.32% | 358B | |
| -0.13% | +7.51% | +33.47% | +48.68% | 366B | |
| -0.95% | +5.93% | +19.86% | +42.48% | 288B | |
| -1.98% | +4.66% | -1.57% | +13.41% | 261B | |
| -0.35% | +6.15% | +45.46% | +52.23% | 235B | |
| -0.75% | +6.18% | +32.03% | +101.15% | 195B | |
| Average | -0.51% | +5.27% | +34.97% | +62.27% | 436.64B | |
| Weighted average by Cap. | -0.32% | +4.93% | +38.82% | +72.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.97B 198B 34.67B 32.09B 29.24B 55.09B 3,700B 56.11B 386B 151B 1,929B 146B 143B 6,156B | 40.36B 205B 35.91B 33.24B 30.28B 57.05B 3,832B 58.12B 399B 157B 1,998B 151B 148B 6,376B |
| Net income | 8.54B 43.29B 7.6B 7.03B 6.41B 12.07B 811B 12.3B 84.52B 33.18B 423B 32.05B 31.36B 1,349B | 9.43B 47.78B 8.39B 7.76B 7.07B 13.33B 895B 13.57B 93.29B 36.62B 467B 35.37B 34.62B 1,489B |
| Net Debt | 41.36B 210B 36.8B 34.06B 31.03B 58.46B 3,927B 59.56B 409B 161B 2,047B 155B 152B 6,534B | 35.3B 179B 31.41B 29.07B 26.48B 49.9B 3,351B 50.83B 349B 137B 1,748B 132B 130B 5,576B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-15 | R$79.65 | +3.44% | 177 |
| 26-10-14 | R$77.00 | +3.49% | 388 |
| 26-10-13 | R$74.40 | +0.18% | 85 |
| 26-10-09 | R$74.27 | -0.71% | 74 |
| 26-10-08 | R$74.80 | +0.92% | 1,089 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
